Delcath Systems, Inc. was founded in 1988 and is based in New York, New York. Delcath Systems, Inc., a development stage company, develops and manufactures devices to administer high dose chemotherapy and other therapeutic agents directly to diseased organs or regions of the body. It focuses on the development of the Delcath PHP System, a Phase III clinical trial product, which isolates the liver from the patient's general circulatory system and delivers high dose of melphalan hydrochloride or other therapeutic agents directly to the liver. The Delcath PHP System kit includes an arterial infusion catheter, a multi-passageway/double balloon catheter, a blood tubing/extracorporeal filtration circuit, two activated carbon hemoperfusion filters, a return catheter/a thin-walled blood sheath, and a series of introducers and related accessories to properly place the catheters. The company also conducts Phase II clinical trials to test the Delcath PHP System with the drug melphalan against liver cancer/hepatocellular tumors, neuroendocrine and adenocarcinoma tumors that have spread to the liver, and melanomas metastatic to the liver that have received prior regional treatment. It has a collaboration with the National Cancer Institute to develop and evaluate the Delcath PHP System device to deliver high-dose melphalan to patients, and to evaluate the use of additional chemotherapy agents with the Delcath PHP System.

Bayer HealthCare Animal Health Division has Fido and Bessie's wellness in mind. The company is part of the health care division of global chemical and pharmaceutical giant Bayer. The Animal Health Division manufactures anti-infectives, insecticides, parasiticides, sedatives, nutritional supplements, vaccines, and other pharmaceuticals for companion (dogs, cats, horses) and farm (cattle, pigs, poultry, bees) animals. Major products include flea and heartworm treatment Advantage and anti-infective Baytril. The division operates more than 50 branch locations worldwide and sells its products in some 120 countries.

Merck OY company, a subsidiary of Germany-based Merck KGaA, manufactures, markets, and distributes prescription and over-the-counter pharmaceutical medicines. Merck OY's prescription drugs fall into targeted therapeutic categories such as diabetes, cardiovascular care, and infertility, and its consumer health care segment primarily consists of nutraceutical (vitamin) products. It also makes select chemical products, including liquid crystals and life science laboratory chemicals.

Pharming Group N.V. is a Netherlands-based biotechnology company. The Company has facilities both in the Netherlands and the United States. Pharming develops products for the treatment of diseases with significant medical needs, including genetic disorders, diseases associated with the immune system, ageing diseases, and nutritional products. The Company’s technologies include platforms for the production of protein therapeutics and technology and processes for the purification and formulation of these products, as well as technologies in the field of DNA repair via its subsidiary DNage BV. Pharming products under development are divided into three categories: biopharmaceuticals, biomaterials, and bio-nutritionals. Products in the most advanced stage of development and closest to commercialization are Rhucin and human lactoferrin for use in food products. Pharming has several partnerships and collaborations with, inter alia, AgResearch, US Army, Aslan and Schering-Plough.

Pain Therapeutics, Inc. was founded in 1998 and is based in San Mateo, California. Pain Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of novel drugs. It has four drug candidates in clinical development programs, which include Remoxy, a novel controlled-release oral capsule form of oxycodone; PTI-202 and PTI-721, which are abuse-resistant forms of opioid drugs; and PTI-188 for the treatment of metastatic melanoma. The company is also developing a technology for the treatment of hemophilia in patients. Pain Therapeutics, Inc. has a strategic alliance with King Pharmaceuticals, Inc. for the development and commercialization of Remoxy, PTI-202, PTI-721, and other abuse-resistant opioid painkillers.

The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey. The Medicines Company, a pharmaceutical company, provides medicines for the treatment of critical care patients worldwide. It markets Angiomax, an intravenous direct thrombin inhibitor for use as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty; and Cleviprex, a dihydropyridine calcium channel blocker, for the control of high blood pressure. The company's development products include cangrelor, an injectable antiplatelet agent that prevents platelet activation and aggregation in the clotting process; Oritavancin, a semi-synthetic lipoglycopeptide antibiotic for the treatment of gram-positive infections; and CU-2010 for the prevention of blood loss during surgery. Its customers include hospital management, physicians, hospital pharmacists, nurses, and other care staff. The Medicines Company sells its products through sales representatives and managers. The company has commercial supply agreement with Lonza Braine S.A. for the development and supply of the Angiomax bulk drug substance.

Insmed Incorporated Company was founded in 1999 and is headquartered in Richmond, Virginia. Insmed Incorporated, a development stage company, engages in the development of recombinant protein drug. The company's primary product includes IPLEX, a complex of recombinant human IGF-1 and its binding protein IGFBP-3 for use in the treatment of several serious medical conditions, as well as conducting a phase III enabling clinical trial for investigating IPLEX as a treatment for myotonic muscular dystrophy. Insmed also engages in various oncology programs, including INSM-18, an orally available small molecule tyrosine kinase inhibitor that has demonstrated selective inhibition of IGF-1 and human epidermal growth factor receptor; and rhIGFBP-3, which is in early clinical development stage for the treatment of breast, prostate, liver, ovarian, and colon cancers. The company also provides Expanded Access Program in Italy to offer IPLEX to physicians for use in their patients with amyotrophic lateral sclerosis. It has a license to Pharmacia AB's portfolio of regulatory filings pertaining to rhIGF; and an agreement with NAPO Pharmaceuticals that gives NAPO the right to develop, manufacture, and commercialize masoprocal products for various indications relating to diabetes, cardiac disease, vascular disease, metabolic disease, and syndrome X.

AdvoCare International can be your ticket to good health, or your ticket to entrepreneurship. The direct sales company offers a variety of vitamin supplements and nutritional products for weight management, sport and athletic performance, skin care, and general wellness. In addition to its grown-up offerings, the firm also sells products for children. AdvoCare markets its products through a force of over 50,000 independent distributors throughout the world. Bolstering the company's image is its slate of endorsers, ranging from professional and collegiate athletes to bodybuilders and musicians.

Stellar Pharmaceuticals Inc. company was founded in 1978 and is based in London, Canada. Stellar Pharmaceuticals Inc. engages in the development and marketing of polysaccharide-based therapeutic products used in the treatment of osteoarthritis and cystitis. It offers NeoVisc, a three injection sodium hyaluronate therapy for the treatment of osteoarthritis; and Uracyst for the treatment of interstitial cystitis, a painful bladder syndrome an inflammatory disease of the urinary bladder wall. The company also has in-licensing agreement for the distribution and sale of BladderChek, a proteomics-based diagnostic test for the diagnosis and monitoring of bladder cancer. Stellar markets its products to medical physicians, pharmacies, hospitals, and patient support groups in Canada through its sales force, as well as out-licenses its products to companies in the United States, Europe, Romania, the Russian Federation, China, Israel, the Middle East, Latin America, the Caribbean, Malaysia, Singapore, and Brunei.

Since its establishment in 1982, Orgenics' objective has been to develop accurate and safe diagnostic products for serious and life-threatening conditions and diseases. Orgenics contributes to the increased awareness and early detection of HIV, infectious diseases, pregnancy and fertility, respiratory diseases, cancer and cardiology through clinical and point-of-care diagnostics. Orgenics delivers products and solutions to partners and customers in over 150 countries around the globe.Orgenics unique and patented ImmunoComb® technology is quick and easy to use, providing high sensitivity and specificity. Instrument free Orgenics' ImmunoComb® kits are ideal for decentralized clinical laboratories, field hospitals and remote rural areas. Orgenics' ImmunoLISA™ system is based on classic ELISA assay principle and is suitable for any laboratory setting.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.